

Technology Guidance

Nivolumab in combination with ipilimumab for untreated unresectable or metastatic colorectal cancer

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion in combination with ipilimumab 50 mg/10 mL injection concentrate, for untreated mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer.

The decision was based on the acceptable clinical effectiveness and pricing proposal by the company.

Funding status

Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion, and ipilimumab 50 mg/10 mL injection concentrate are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 December 2026.

Clinical indication, subsidy class and MediShield Life claims eligibility for nivolumab and ipilimumab are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class (implementation date)	Eligible for MediShield Life claims (implementation date)
Nivolumab 40 mg/4 mL, 100 mg/10 mL and 240 mg/24 mL concentrate for solution for infusion Ipilimumab 50 mg/10 mL injection concentrate	Nivolumab in combination with ipilimumab for untreated mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer. The doses of nivolumab and ipilimumab should not exceed: 240mg nivolumab and 1 mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240 mg every 2 weeks or 480mg every 4 weeks as a single agent. Nivolumab may be given as a weight-based or flat dosing regimen. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses.	MAF (1 Dec 2026)	Yes ¹ (1 Dec 2026)

Abbreviations: MAF, Medication Assistance Fund.

¹ Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.